comparemela.com

Latest Breaking News On - Prnewswire brand institute - Page 4 : comparemela.com

Brand Institute Partners on Brand Name Development for FDA Approved Treatment for the Chronic Management of Urea Cycle Disorders (UCDs)

/PRNewswire/ Brand Institute is proud to announce its work with Duchesnay in developing the brand name PHEBURANE®. PHEBURANE® (sodium phenylbutyrate) is.

United statesJamesl dettoreJames dettoreLucane pharmaDrug safety instituteBrand instituteWorld health organizationDrug administrationBrand institute incAmerican medical associationPrnewswire brand instituteEuropean medicines agencyHealth canadaDrug safetySafety institute

Former FDA DMEPA Director and Head of Brand Institute s Regulatory Division Updates the Company s Services Based on Recent FDA Safety Guidance

/PRNewswire/ Brand Institute, the global leader in pharmaceutical and healthcare related name development, is pleased to announce incorporation of the.

United statesJames dettoreDrug safety instituteBrand instituteOffice of surveillanceDivision of medication error preventionCommission patient safety advisory groupDrug administrationNational coordinating council for medication errorBrand institute incInternational medication safety networkPrnewswire brand instituteHealth canadaTodd bridgesSafety considerationsContainer labels

FDA Approves Orphalan s CUVRIOR™ (trientine tetrahydrochloride), the first treatment for Wilson s disease in over five decades

/PRNewswire/ Brand Institute is proud to announce working with rare disease specialist, Orphalan, in developing the brand name CUVRIOR™, approved by the.

United statesJamesl dettoreJames dettoreDrug safety instituteBrand instituteWorld health organizationDrug administrationDrug administration onBrand institute incDrug safety institute teamAmerican medical associationPrnewswire brand instituteEuropean medicines agencyHealth canadaUnited states foodDrug safety

FDA Approves Alymsys® (bevacizumab-maly), a Biosimilar of Bevacizumab by Amneal Pharmaceuticals, Inc , developed by mAbxience

/PRNewswire/ Brand Institute is proud to announce its successful partnership with Amneal Pharmaceuticals in developing the brand name ALYMSYS®, under which.

United statesJamesl dettoreJames dettoreAmneal pharmaceuticalsDrug safety instituteBrand instituteWorld health organizationDrug administrationBrand institute incDrug safety institute teamAmerican medical associationPrnewswire brand instituteEuropean medicines agencyHealth canadaDrug safetySafety institute

European Medicines Agency Approves OXBRYTA® (voxelotor), First Treatment Approved in the EU to Target the Cause of Sickle Cell Disease

/PRNewswire/ Brand Institute is proud to announce its successful partnership with Global Blood Therapeutics (GBT) in naming their EMA-approved therapy,.

United statesScott piergrossiJamesl dettoreDrug safety instituteBrand instituteWorld health organizationBrand institute incDrug safety institute teamAmerican medical associationPrnewswire brand instituteHealth canadaGlobal blood therapeuticsDrug safetySafety institute

vimarsana © 2020. All Rights Reserved.